Loading...
Start 2018-10-31T11:41:47+00:00

Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.

A simple blood sample

DiviTum® is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum® biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.

Read more about DiviTum

New unique data from US breast cancer congress

The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum® measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum® may thus serve as a non-invasive marker and early response indicator of the anti-proliferative effect of CDK4/6 inhibitors like palbociclib.

Read more about the study

About Biovica

Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.

Read more about Biovica

Interim Report May-January 2018/2019

Significant events during the third quarter · Abstract was presented at San Antonio Breast Cancer Symposium · New office and staff in USA Significant events after the end of the period · Abstract to be presented at AACR in April · Shares now traded on Nasdaq First North Premier · Lars Holmqvist elected as new Chairman · Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.

Read More

Report from Biovica’s Extra Shareholder’s Meeting on March 20, 2019

Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.

Read More

Biovica announces two new customers and sales of 1,5 MSEK

Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe.

Read More

BEST POSSIBLE TREATMENT FROM DAY ONE

Breast cancer

Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum® biomarker assay, aim to increase survival and improve quality of life.

Read more about market need

Clinical trials and Collaborations

Biovica has successfully worked to realize its vision for Divitum® by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).

Read more about clinical trials